All Voices
Biohacker· Evidence Review

Bryan Johnson

The $2M/year longevity experiment

Last reviewed: March 30, 2026Topics: Longevity, Biohacking, Biomarkers, Epigenetic Age
Bryan Johnson speaking at the Tribeca Disruptive Innovation Awards.
Photo: Tribeca Disruptive Innovation / Wikimedia Commons, CC BY-SA 3.0 · source · 2017

Bio

Bryan Johnson is a tech entrepreneur who sold Braintree to PayPal for $800 million in 2013 and now spends roughly $2 million per year on a highly publicized anti-aging protocol called Blueprint. He works with a team of ~30 doctors and scientists, tracks 100+ biomarkers, and has become one of the most visible popularizers of the longevity movement — and also one of its most polarizing figures.

Background

Johnson's background is in software and payments, not biology. After exiting Braintree, he founded Kernel (brain-computer interfaces) and OS Fund (deep-tech investing). His longevity work began as a personal experiment around 2020 and grew into Blueprint — a protocol, supplement line, and media property. He is not a trained scientist, clinician, or researcher and has no peer-reviewed publications on aging biology.

What They Do

Johnson publishes his full protocol, biomarker data, and results openly — an unusual level of transparency for self-experimentation. Blueprint includes a strict ~2,250-calorie vegan diet, 60+ daily supplements, 1 hour of daily exercise, 8+ hours of sleep, regular red-light therapy, hyperbaric oxygen, plasma exchange (discontinued), rapamycin (discontinued), and quarterly full-body MRI and DEXA scans. He commercialized Blueprint as a consumer supplement line in 2024.

Research Record

No peer-reviewed research record in this field. This profile does not have published research contributions in longevity or gene editing. Their influence comes from popularization and self-experimentation, not primary research.

Our Evidence Summary

Johnson's protocol mixes interventions with strong evidence (exercise, sleep, Mediterranean-style diet) with interventions that are weak, unproven, or experimental (high-dose supplement stacks, plasma exchange, gene therapy tourism). His individual biomarker improvements are real but cannot be generalized — they reflect one data point of one genetically unique person with unlimited resources. The field's senior researchers are divided: some praise the transparency, others criticize the cherry-picking and the commercial conflicts.

Claim-by-Claim Evidence Review

Strong Evidence

A nutrient-rich plant-forward diet can slow biological aging

Multiple large randomized trials (PREDIMED, CALERIE) show Mediterranean-pattern and calorically moderate diets reduce all-cause mortality and slow epigenetic aging markers.

Strong Evidence

Daily structured exercise adds years of healthspan

Exercise is the single most-studied longevity intervention. Meta-analyses consistently show it reduces all-cause mortality and improves nearly every hallmark of aging.

Strong Evidence

Sleep optimization (consistent 7-9 hours) improves biological age markers

Large epidemiological studies and mechanistic work link sleep to metabolic, cognitive, and immune aging. Johnson's rigorous sleep tracking is well-supported.

Limited Evidence

Taking 60+ daily supplements reverses aging

Very few supplements in Blueprint's stack have high-quality human trial data showing longevity benefits. Individual components (omega-3, vitamin D, creatine) have some evidence, but the combined 'stack effect' is not proven. Risk of interactions and liver burden is non-trivial.

Speculative

Plasma exchange reverses aging

Based on mouse parabiosis experiments that do not translate cleanly to humans. Very small human trials exist but no RCT has demonstrated a longevity benefit. Johnson has since deprioritized this intervention.

Speculative

Gene therapy (follistatin) for longevity

Johnson received an off-label follistatin gene therapy in Honduras in 2025. The intervention has no human efficacy data for longevity, no peer-reviewed safety profile, and was delivered outside any regulatory framework. Most researchers consider this reckless.

Moderate Evidence

Epigenetic age (Horvath clock) is a reliable marker of 'real' aging

Epigenetic clocks correlate with mortality risk in populations, but their use as an individual intervention-response marker is debated. Short-term clock changes may not reflect underlying biological aging.

Related Reading

Editorial note: This page evaluates the public claims and protocols of a third party. We do not receive compensation from any of the people profiled and have no affiliation with them. Evidence levels are assigned by reviewing primary literature and reflect the state of the science as of March 2026. Science evolves — we update these reviews when new evidence emerges. This is not medical advice; consult a qualified physician before changing your health practices.